Trial Profile
A randomized, open-label study of the effect of MabThera, with and without fludarabine/cyclophosphamide, on progression-free survival in patients with chronic lymphocytic leukemia.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Sponsors Roche
- 08 Dec 2020 Results of pooled analysis (CLL7, CLL8, CLL10, CLL11 and CLL2M)presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
- 29 Aug 2016 Results (n=554) of this and other trial (CLL10) published in the Journal of Clinical Oncology (2016).
- 08 Dec 2015 Results (pooled analysis of CLL8 and CLL10 studies) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology (n = 635).